Psmg2 Inhibitors

Chemical inhibitors of Psmg2 can impede its function through various mechanisms that disrupt different cellular processes. Oligomycin A targets mitochondrial ATP synthase, creating an energy-deficient state that ultimately affects energy-dependent proteins such as Psmg2. Similarly, compounds like Bortezomib and MG-132 inhibit the ubiquitin-proteasome pathway, leading to an accumulation of proteins that require degradation. This accumulation can overwhelm the protein quality control systems in which Psmg2 functions, indirectly inhibiting its activity. Cycloheximide, on the other hand, inhibits protein synthesis, thereby reducing the pool of new proteins that would typically require the chaperoning services of Psmg2, thereby reducing its functional load.

Furthermore, Tunicamycin inhibits N-linked glycosylation, which can affect the folding and function of substrates that Psmg2 would normally act upon. Eeyarestatin I disrupts ER-associated degradation pathways, which also impacts protein quality control mechanisms involving Psmg2. Withaferin A and Epoxomicin, both proteasome inhibitors, lead to a similar outcome as Bortezomib and MG-132 by preventing the degradation of ubiquitinated proteins, thereby causing a backlog that indirectly impedes Psmg2's role. Additionally, Piperlongumine increases reactive oxygen species within cells, leading to oxidative stress conditions that can inhibit Psmg2 activity. Puromycin causes premature chain termination during protein translation, leading to a decreased availability of nascent proteins for Psmg2 to act upon. Lastly, Lactacystin and Salubrinal inhibit the proteasome and eIF2α dephosphorylation, respectively, both of which lead to reduced protein synthesis or accumulation of polyubiquitinated proteins, further inhibiting Psmg2's function within the cell's protein quality control systems.